Cite
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
MLA
Nuciforo, P. G., et al. “Benefit to Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapies in HER2-Positive Primary Breast Cancer Is Independent of Phosphatase and Tensin Homolog Deleted from Chromosome 10 (PTEN) Status.” Annals of Oncology, vol. 26, no. 7, July 2015, pp. 1494–500. EBSCOhost, https://doi.org/10.1093/annonc/mdv175.
APA
Nuciforo, P. G., Aura, C., Holmes, E., Prudkin, L., Jimenez, J., Martinez, P., Ameels, H., de la Peña, L., Ellis, C., Eidtmann, H., Piccart-Gebhart, M. J., Scaltriti, M., & Baselga, J. (2015). Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Annals of Oncology, 26(7), 1494–1500. https://doi.org/10.1093/annonc/mdv175
Chicago
Nuciforo, P. G., C. Aura, E. Holmes, L. Prudkin, J. Jimenez, P. Martinez, H. Ameels, et al. 2015. “Benefit to Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapies in HER2-Positive Primary Breast Cancer Is Independent of Phosphatase and Tensin Homolog Deleted from Chromosome 10 (PTEN) Status.” Annals of Oncology 26 (7): 1494–1500. doi:10.1093/annonc/mdv175.